Winter Is Coming

[TheWallnerus]

POLAR

SABCS Dec 2022

Med students... you've been warned!

---

Members don't see this ad.

 

[OTN]

Will first need to be validated in a prospective randomized clinical trial. Once it is, I do expect this to change management and radonc volume significantly.

It will be nice to have something definitive to hang my hat on and say "this is why you need breast RT".

 

[RadOncDoc21]

How about the benefit of not having to do 5 years of HRT?

 

[RADONC4285]

Agree this will need prospective validation before it becomes practice changing. We also have some studies in the pipeline looking at endocrine therapy vs RT and I expect RT to win/be equivalent, That would counter some of the RT omission trends. Hence I don't expect things to change drastically in the next 10 to 15 years for breast in terms of # of pts getting RT. Nonetheless, this is perfectly in line with our overall shrinking footprint and will certainly be a major factor down the road. Definitely would not be looking into rad onc as a current med student

 

[temujim]

Will first need to be validated in a prospective randomized clinical trial. Once it is, I do expect this to change management and radonc volume significantly.

It will be nice to have something definitive to hang my hat on and say "this is why you need breast RT".

I dunno; did oncotype have prospective data when it entered routine practice?

Imagine this will be ordered by med oncs and surgeons who will then not send the low risk patients.

Not to say any of the above is right, but probably how it will go down.

 

[metallica81788]

I dunno; did oncotype have prospective data when it entered routine practice?

Imagine this will be ordered by med oncs and surgeons who will then not send the low risk patients.

Not to say any of the above is right, but probably how it will go down.

That would be so frustrating to be cut out of the loop without even a word to say
However there is precedent - look at pancreas, lymphoma

We would have to rely on the lazy surgeons/medoncs that dump to radonc "for discussion"

 

[RadOncDoc21]

That would be so frustrating to be cut out of the loop without even a word to say
However there is precedent - look at pancreas, lymphoma

We would have to rely on the lazy surgeons/medoncs that dump to radonc "for discussion"

Recommend Multi-D clinic/discussion prior to surgery if logistically possible.

 

[BobbyHeenan]

It will also get quick approval by insurance I'd imagine, because I bet this test costs less than a course of radiation.

 

[fiji128]

That would be so frustrating to be cut out of the loop without even a word to say
However there is precedent - look at pancreas, lymphoma

We would have to rely on the lazy surgeons/medoncs that dump to radonc "for discussion"

In the long run surgeons aren't going to send us all their breast patients for "discussion" once they realize those with a low score don't need to be inconvenienced/confused by having said "discussion." See above examples regarding pancreas and lymphoma.

 

[BobbyHeenan]

In the long run surgeons aren't going to send us all their breast patients for "discussion" once they realize those with a low score don't need to be inconvenienced/confused by having said "discussion." See above examples regarding pancreas and lymphoma.

I would think that this surgeon ordering the test phenomenon won't take off too much until the test enters NCCN guidelines.

The DCISionRT score is being ordered some in my area by non-rad oncs, but not across the board.

 

[radiation]

Dont they already have something similar for OncotypeDX DCIS? Feels like uptake for that has been pretty low

https://precisiononcology.exactsciences.com/patients-and-caregivers/understanding-your-diagnosis/breast-cancer/breast-dcis-score

Also the long term updates on all these studies always show the curves widening the most after 10 years

 

[DebtRising]

Great use of personalized medicine to spare patients unnecessary treatment if validated.

Terrible foresight / greed by the senior and leaders of our field to have no mechanism or rationale discussion to modify number of trainees as indications and fractions shrink. Breast is a large driver of how we benefit society. Without that, society needs less of us. But we are training more of us. Golden parachutes for the old guard!

 

[BobbyHeenan]

Dont they already have something similar for OncotypeDX DCIS? Feels like uptake for that has been pretty low

https://precisiononcology.exactsciences.com/patients-and-caregivers/understanding-your-diagnosis/breast-cancer/breast-dcis-score

Also the long term updates on all these studies always show the curves widening the most after 10 years

View attachment 364193

The oncotype DCIS data is not as robust IMO as DCISionRT.

My experience with DCISionRT score though is it predicts a number pretty daggone close to what I would have told the patient anyway without the score based upon a number of well done DCIS trials like RTOG 9804.

I do think it can be a useful tool in borderline cases. But if you come to me with an ER negative DCIS with a close-ish margin or young age, I don't need that score IMO.

 

[RickyScott]

I dunno; did oncotype have prospective data when it entered routine practice?

Imagine this will be ordered by med oncs and surgeons who will then not send the low risk patients.

Not to say any of the above is right, but probably how it will go down.

Party is just getting started. More personalized biomarkers/Ct dna will follow.

 

[medgator]

Party is just getting started. More personalized biomarkers/Ct dna will follow.

Pretty much any post op indication could be fair game eventually

 

[metallica81788]

30/5 to all!

Get it in while gettin' is still good! 5>0

 

[BobbyHeenan]

Party is just getting started. More personalized biomarkers/Ct dna will follow.

I think this is where we're headed. Gonna take a while to get there. But post op indications in 10 years gonna look a LOT different.

 

[Sheldor]

I think this is where we're headed. Gonna take a while to get there. But post op indications in 10 years gonna look a LOT different.

We'll be treating half the patients as today with twice the doctors! Unbelievable

 

[NotMattSpraker]

Great use of personalized medicine to spare patients unnecessary treatment if validated.

Terrible foresight / greed by the senior and leaders of our field to have no mechanism or rationale discussion to modify number of trainees as indications and fractions shrink. Breast is a large driver of how we benefit society. Without that, society needs less of us. But we are training more of us. Golden parachutes for the old guard!

This, plus totally bungled implementation of IMRT for breast, plus failure to speak up in defense of RT as people have tried over and over and over again to make it go away in early stage breast cancer.

Hey I made it 3 whole days in to 2023 before saying this... we need better leadership!

 

[TheWallnerus]

That would be so frustrating to be cut out of the loop without even a word to say

That's one take. Another take is, if there's no indication for RT, there's no need for a #radonc to be in the loop.

In the long run surgeons aren't going to send us all their breast patients for "discussion" once they realize those with a low score don't need to be inconvenienced/confused by having said "discussion."

As it should be, imho (if there's agreed to be no need for RT).

I would think that this surgeon ordering the test phenomenon won't take off too much until the test enters NCCN guidelines.

That is probably going to be true, but sometimes a standard sets foot as a standard (at least in the eyes of surgeons/med oncs) before NCCN declares it a standard. I don't recall if NCCN explicitly says don't do radiation in low-risk older women with breast cancer, but it's standard in the eyes of many:

What I see as a possibility: one day... it will just change. POLAR will become standard. And rad onc's won't really be consulted about the change or be part of the change one way or the other.

Dont they already have something similar for OncotypeDX DCIS?

Breast is a large driver of how we benefit society. Without that, society needs less of us.

That would be logical.

Also the long term updates on all these studies always show the curves widening the most after 10 years

It looks like curve for POLAR-low and getting RT will separate for higher local failure after 10y vs no RT.

The Lord giveth, and the Lord separateth away.

Pretty much any post op indication could be fair game eventually

“How can we minimize morbidity while preserving outcomes for locally advanced rectal cancer?… There are a few ways that we can approach this. The first is omission of radiation.”

 

[RickyScott]

Forego Radiotherapy for Women With Low-Risk Luminal A Breast Cancer?

Study shows 5-year local recurrence rate of 2.3% with lumpectomy and endocrine therapy alone

www.medpagetoday.com

“Corey speers MD, PhD, of the University of Michigan in Ann Arbor. "It really is a personalized approach to identifying these patients. Identifying these patients based on their intrinsic molecular subtype of the tumor, based on the biology, and not just clinical and pathological features, suggests we can really identify these patients who are at very low risk of their cancer coming back."

 

[NotMattSpraker]

“How can we minimize morbidity while preserving outcomes for locally advanced rectal cancer?… There are a few ways that we can approach this. The first is omission of radiation.”

I love weird editorials and this is up there for sure! She contradicts herself an impressive number of times.

 

[Fpg1245]

Forego Radiotherapy for Women With Low-Risk Luminal A Breast Cancer?

Study shows 5-year local recurrence rate of 2.3% with lumpectomy and endocrine therapy alone

www.medpagetoday.com

“Corey speers MD, PhD, of the University of Michigan in Ann Arbor. "It really is a personalized approach to identifying these patients. Identifying these patients based on their intrinsic molecular subtype of the tumor, based on the biology, and not just clinical and pathological features, suggests we can really identify these patients who are at very low risk of their cancer coming back."

This is idiotic not just because it omits RT but many of these women don’t tolerate an AI. We literally have bent over backwards with our balls in a knot to accommodate people getting RT with short course and this is what we get.

 

[radiation]

It looks like curve for POLAR-low and getting RT will separate for higher local failure after 10y vs no RT.

The Lord giveth, and the Lord separateth away.

a lot of curves look like a lot of things when presented as small unpublished abstracts, good thing we have trials and statistics

 

[radiation]

That's one take. Another take is, if there's no indication for RT, there's no need for a #radonc to be in the loop.

As it should be, imho (if there's agreed to be no need for RT).

That is probably going to be true, but sometimes a standard sets foot as a standard (at least in the eyes of surgeons/med oncs) before NCCN declares it a standard. I don't recall if NCCN explicitly says don't do radiation in low-risk older women with breast cancer, but it's standard in the eyes of many:

What I see as a possibility: one day... it will just change. POLAR will become standard. And rad onc's won't really be consulted about the change or be part of the change one way or the other.

That would be logical.


It looks like curve for POLAR-low and getting RT will separate for higher local failure after 10y vs no RT.

The Lord giveth, and the Lord separateth away.


“How can we minimize morbidity while preserving outcomes for locally advanced rectal cancer?… There are a few ways that we can approach this. The first is omission of radiation.”

If you think running retrospective analysis on prospective clinical trials is the stuff that scientific revolutions are made out of, then you must have lost your mind when you saw this

Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis

The biological effect of radiotherapy, as quantified by GARD, is significantly associated with time to first recurrence and overall survival for patients with cancer treated with radiation. It is predictive of radiotherapy benefit, and physical dose of radiation is not. We propose integration of...

www.thelancet.com

 

[Fpg1245]

That's one take. Another take is, if there's no indication for RT, there's no need for a #radonc to be in the loop.

As it should be, imho (if there's agreed to be no need for RT).

That is probably going to be true, but sometimes a standard sets foot as a standard (at least in the eyes of surgeons/med oncs) before NCCN declares it a standard. I don't recall if NCCN explicitly says don't do radiation in low-risk older women with breast cancer, but it's standard in the eyes of many:

What I see as a possibility: one day... it will just change. POLAR will become standard. And rad onc's won't really be consulted about the change or be part of the change one way or the other.

That would be logical.


It looks like curve for POLAR-low and getting RT will separate for higher local failure after 10y vs no RT.

The Lord giveth, and the Lord separateth away.


“How can we minimize morbidity while preserving outcomes for locally advanced rectal cancer?… There are a few ways that we can approach this. The first is omission of radiation.”

Never mind they coming up with a more efficient way to deliver freaking 6 cycles of folfox. Just get rid of RT.

 

[NotMattSpraker]

If you thinking running retrospective analysis on prospective clinical trials is the stuff that scientific revolutions are made out of, ...

Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis

The biological effect of radiotherapy, as quantified by GARD, is significantly associated with time to first recurrence and overall survival for patients with cancer treated with radiation. It is predictive of radiotherapy benefit, and physical dose of radiation is not. We propose integration of...

www.thelancet.com

Damn I thought you were going to end with "then you must be designing the ASTRO 2023 plenary". Great joke! No worries, I got you 🙂

 

[radoncftw]

How about the benefit of not having to do 5 years of HRT?

they should do a study looking at patient reported QOL of endocrine therapy vs. RT.
Or like a regret study (similar to what do they for patients who get RT vs. RP for prostate cancer)

we talk so much about being "patient centered"..

 

[communitydoc13]

If you think running retrospective analysis on prospective clinical trials is the stuff that scientific revolutions are made out of, then you must have lost your mind when you saw this

Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis

The biological effect of radiotherapy, as quantified by GARD, is significantly associated with time to first recurrence and overall survival for patients with cancer treated with radiation. It is predictive of radiotherapy benefit, and physical dose of radiation is not. We propose integration of...

www.thelancet.com

I'm can't discern any meaningful value to GARD. The type of thing that is appealing on the surface, but not meaningful in practice. GARD is gonna tell me to give 50 or 60 Gy? Please.

 

[TheWallnerus]

If you think running retrospective analysis on prospective clinical trials is the stuff that scientific revolutions are made out of, then you must have lost your mind when you saw this

Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis

The biological effect of radiotherapy, as quantified by GARD, is significantly associated with time to first recurrence and overall survival for patients with cancer treated with radiation. It is predictive of radiotherapy benefit, and physical dose of radiation is not. We propose integration of...

www.thelancet.com

No no no. Not saying that. I am saying Oncology is a Culture (intentional capitalization). And scientific revolution is about culture and cultural changes and the humans that drive change and not so much about science and data and proof (not as much as one would think). And increasingly rad onc is not participating and driving the Culture of Oncology but more like "logs floating in the stream of life." I am speaking to Kuhn's "paradigms." For radiation oncologists e.g. it is yet to be seen if the "oligometastatic paradigm" is a Kuhnian paradigm; it's not looking favorable imho.

Don't feel like it's telling tales out of school to observe that The Culture of Oncology is heavy into rad onc minimization right now.

they should do a study looking at patient reported QOL of endocrine therapy vs. RT.

Use of "they" here is what I'm getting at above; the "they" is Oncology. And "they" will not let this study be a new paradigm even if it shows LC's are going to be similar. Just being real. And we know they would be similar, we don't even need that study... there's reasonable enough data already to suggest such a study's outcome.

I love weird editorials and this is up there for sure!

The Culture of Oncology! It seems weird to us. But we are rad oncs maybe not in tune with the Culture.

 

[communitydoc13]

And increasingly rad onc is not participating and driving the Culture of Oncology but more like "logs floating in the stream of life."

It's just inevitable. There are radoncs who are true molecular researchers and are very much involved in driving oncology culture. Everyone else, not so much. To the degree that we have "an agenda" with our research to support our lone intervention, we will never be players. To the degree that we are open minded with our research, we will continue to undermine our lone intervention.

As refining indications for XRT downward is easy, many young academic radoncs participate in this enterprise. I don't blame them. I do blame them for believing they need more trainees.

 

[SBRTreble]

I'm can't discern any meaningful value to GARD. The type of thing that is appealing on the surface, but not meaningful in practice. GARD is gonna tell me to give 50 or 60 Gy? Please.

Respectfully: why do you prescribe 60 Gy? Is there any biological basis to that decision? Or is it because it is an arbitrary dose that we've always done for Stage # (fill in the blank) cancer?

 

[TheWallnerus]

Respectfully: why do you prescribe 60 Gy? Is there any biological basis to that decision? Or is it because it is an arbitrary dose that we've always done for Stage # (fill in the blank) cancer?

That you Jake 🙂

Rad oncs are very capriciously choosy about when and when not to use biology. I think I use biology the most when I give 24 Gy in one fraction to a teeny tiny brain met. I use it the least when I have to back the dose down lower when the brain met is larger.

 

[communitydoc13]

Respectfully: why do you prescribe 60 Gy? Is there any biological basis to that decision? Or is it because it is an arbitrary dose that we've always done for Stage # (fill in the blank) cancer?

Cause it's worked (meaning demonstrated some disease control benefit with acceptable toxicity) in large groups of patients and neither dose escalation nor de-escalation trials have indicated better clinical outcomes.

Now, is it possible to tell that pt A with a given disease only needs 50 Gy and pt B needs 60? That's a tough nut to crack and may not even be worth it if things like safety profile are already reasonable. It certainly doesn't engender paradigm change in the way that multiple new effective therapeutics do.

At some limit, I question whether personalized medicine in it's extreme is even conducive to confirmation by prospective randomized trials. Can we even accrue enough patients with the "exact same molecular signature" and then randomize them to different therapies. That's why we end up bifurcating very detailed molecular assays with hard cutoffs and then testing. We inevitably choose the wrong strategy for some patients with this approach, and whether it is better than other, data driven but not molecularly driven decision making tools, is unclear to me to this day.

 

[radiation]

No no no. Not saying that. I am saying Oncology is a Culture (intentional capitalization). And scientific revolution is about culture and cultural changes and the humans that drive change and not so much about science and data and proof (not as much as one would think). And increasingly rad onc is not participating and driving the Culture of Oncology but more like "logs floating in the stream of life." I am speaking to Kuhn's "paradigms." For radiation oncologists e.g. it is yet to be seen if the "oligometastatic paradigm" is a Kuhnian paradigm; it's not looking favorable imho.

Don't feel like it's telling tales out of school to observe that The Culture of Oncology is heavy into rad onc minimization right now.

Use of "they" here is what I'm getting at above; the "they" is Oncology. And "they" will not let this study be a new paradigm even if it shows LC's are going to be similar. Just being real. And we know they would be similar, we don't even need that study... there's reasonable enough data already to suggest such a study's outcome.


The Culture of Oncology! It seems weird to us. But we are rad oncs maybe not in tune with the Culture.

I am not sure I buy this idea that intentional omission of radiation is some new thing signaling an age where rad onc is actively being minimized. People have always tried to come up with ways to eliminate or reduce RT, and its not even new for breast (the oncotype dx DCIS data has been around for over a decade at this point) and people have been doing RT breast omission studies since breast RT became a standard of care.

To me, trying to keep breast and prostate as our bread and butter and clinging on to how things have always been done is a surefire way to become "logs floating in the stream of life." Rad onc is changing, oversupply is real, and there is not likely going to be a "soft landing" for people not willing/able to adapt with the changing landscape of oncology. Conversely, I actually think an overall larger pool of rad oncs is actually going to help the field in the long, long term (not salary wise though unfortunately). The smaller the specialty we are, the easier it would be for the rest of oncology to leave us behind. But the fact its, we have a bigger footprint manpower wise than we ever have had and its up to us on how to best leverage that going forward

 

[RadOncDoc21]

I am not sure I buy this idea that intentional omission of radiation is some new thing signaling an age where rad onc is actively being minimized. People have always tried to come up with ways to eliminate or reduce RT, and its not even new for breast (the oncotype dx DCIS data has been around for over a decade at this point) and people have been doing RT breast omission studies since breast RT became a standard of care.

To me, trying to keep breast and prostate as our bread and butter and clinging on to how things have always been done is a surefire way to become "logs floating in the stream of life." Rad onc is changing, oversupply is real, and there is not likely going to be a "soft landing" for people not willing/able to adapt with the changing landscape of oncology. Conversely, I actually think an overall larger pool of rad oncs is actually going to help the field in the long, long term (not salary wise though unfortunately). The smaller the specialty we are, the easier it would be for the rest of oncology to leave us behind. But the fact its, we have a bigger footprint manpower wise than we ever have had and its up to us on how to best leverage that going forward

I like and welcome the optimism but oversupply isn’t good. It’s like having an oversupply of termites or syphilllis.

 

[taserlaser]

I like and welcome the optimism but oversupply isn’t good. It’s like having an oversupply of termites or syphilllis.

Don’t you mean catfish?

 

[medgator]

I am not sure I buy this idea that intentional omission of radiation is some new thing signaling an age where rad onc is actively being minimized. People have always tried to come up with ways to eliminate or reduce RT, and its not even new for breast (the oncotype dx DCIS data has been around for over a decade at this point) and people have been doing RT breast omission studies since breast RT became a standard of care.

To me, trying to keep breast and prostate as our bread and butter and clinging on to how things have always been done is a surefire way to become "logs floating in the stream of life." Rad onc is changing, oversupply is real, and there is not likely going to be a "soft landing" for people not willing/able to adapt with the changing landscape of oncology. Conversely, I actually think an overall larger pool of rad oncs is actually going to help the field in the long, long term (not salary wise though unfortunately). The smaller the specialty we are, the easier it would be for the rest of oncology to leave us behind. But the fact its, we have a bigger footprint manpower wise than we ever have had and its up to us on how to best leverage that going forward

We are increasing supply by opening unnecessary, objectively weak programs becoming the easiest specialty in the match for US grads to match into

And you think that's a good thing?

 

[Fpg1245]

I am not sure I buy this idea that intentional omission of radiation is some new thing signaling an age where rad onc is actively being minimized. People have always tried to come up with ways to eliminate or reduce RT, and its not even new for breast (the oncotype dx DCIS data has been around for over a decade at this point) and people have been doing RT breast omission studies since breast RT became a standard of care.

To me, trying to keep breast and prostate as our bread and butter and clinging on to how things have always been done is a surefire way to become "logs floating in the stream of life." Rad onc is changing, oversupply is real, and there is not likely going to be a "soft landing" for people not willing/able to adapt with the changing landscape of oncology. Conversely, I actually think an overall larger pool of rad oncs is actually going to help the field in the long, long term (not salary wise though unfortunately). The smaller the specialty we are, the easier it would be for the rest of oncology to leave us behind. But the fact its, we have a bigger footprint manpower wise than we ever have had and its up to us on how to best leverage that going forward

What in the hell are you babbling about?

 

[flannery o'connor]

This is absolutely hilarious for a multitude of reasons. We all know surgeons and the chemo doctors would never in a million years allow a study that will enable omission of their modality although a similar study would easily validate omission of chemo and/or surgery in probably at least 30-40% of malignancies.

I’m cracking up here picturing a bunch of bow tied ROs with rabbinical knowledge of every breast ca study published seething silently and impotently in their usual back seats of the breast MDT while surgeons and the chemo doctors continue to push their treatment with no credible evidence except the same shoddy studies handed to them by drug reps.

If you asked 10000 women what they found more helpful and more tolerable between RT and any form of systemic therapy not one would say they would raise their head in support of the chemo doctors.

We have known for more than 50 years that definitive Rt for early breast gives us the exact same control rates as WLE +RT but we choose to intentionally omit the most important single therapy from management. LMAO. Not a single trial looking at definitive RT in the population and omission of surgery, even though the Japanese are getting equivalent for SABR in the cohort. Laughable.

At the end of the day patients lose and locoregional control rates lose. The chemo guys get more patients and inflict more misery upon women. We continue to be pushed around by people in our profession who wouldn’t even be allowed into medical school in a rational world. Clown world indeed, folks.

 

[flannery o'connor]

This is absolutely hilarious for a multitude of reasons. We all know surgeons and the chemo doctors would never in a million years allow a study that will enable omission of their modality although a similar study would easily validate omission of chemo and/or surgery in probably at least 30-40% of malignancies.

I’m cracking up here picturing a bunch of bow tied ROS with rabbinical knowledge of every breast ca study published seething silently and impotently in their usual back seats of the breast MDT while surgeons and the chemo doctors continue to push their treatment with no credible evidence except the same shoddy studies handed to them by drug reps.

If you asked 10000 women what they found more helpful and more tolerable between RT and any form of systemic therapy not one would say they would raise their head in support of the chemo doctors.

We have known for more than 50 years that definitive Rt for early breast gives us the exact same control rates as WLE +RT but we choose to intentionally omit the most important single therapy from management. LMAO. Not a single trial looking at definitive RT in the population and omission of surgery, even though the Japanese are getting equivalent for SABR in the cohort. Laughable.

At the end of the day patients lose and locoregional control rates lose. The chemo guys get more patients and inflict more misery upon women. We continue to be pushed around by people in our profession who wouldn’t even be allowed into medical school in a rational world. Clown world indeed, folks.

 

[Barcelona PSG]

This is absolutely hilarious for a multitude of reasons. We all know surgeons and the chemo doctors would never in a million years allow a study that will enable omission of their modality although a similar study would easily validate omission of chemo and/or surgery in probably at least 30-40% of malignancies.

I’m cracking up here picturing a bunch of bow tied ROS with rabbinical knowledge of every breast ca study published seething silently and impotently in their usual back seats of the breast MDT while surgeons and the chemo doctors continue to push their treatment with no credible evidence except the same shoddy studies handed to them by drug reps.

If you asked 10000 women what they found more helpful and more tolerable between RT and any form of systemic therapy not one would say they would raise their head in support of the chemo doctors.

We have known for more than 50 years that definitive Rt for early breast gives us the exact same control rates as WLE +RT but we choose to intentionally omit the most important single therapy from management. LMAO. Not a single trial looking at definitive RT in the population and omission of surgery, even though the Japanese are getting equivalent for SABR in the cohort. Laughable.

At the end of the day patients lose and locoregional control rates lose. The chemo guys get more patients and inflict more misery upon women. We continue to be pushed around by people in our profession who wouldn’t even be allowed into medical school in a rational world. Clown world indeed, folks.

These are the kind of trials we need i guess

 

[flannery o'connor]

Thats dope! Now how many of us would post this in a breast MDT?
We know metaplastic can be managed RT only...TNBC should be similar?

 

[flannery o'connor]

I see no reason why an early stage er+ grade elderly couldn't have hypofractionated RT only? Addition of surgery unlikely to provide benefit. Surely one can devise a validation program for this?

 

[RadOncDoc21]

Breast is the worst!

 

[flannery o'connor]

Breast is the worst!

They're all the worst now.

 

[TheWallnerus]

Whole breast IMRT as standard of care for all whole breast RT lookin’ better and better!

 

[medgator]

I see no reason why an early stage er+ grade elderly couldn't have hypofractionated RT only? Addition of surgery unlikely to provide benefit. Surely one can devise a validation program for this?

I offer it quite a bit. If a woman is concerned about being compliant with 5 years of an AI, i tell them a short course of RT becomes even more important to consider

 

[medgator]

I am not sure I buy this idea that intentional omission of radiation is some new thing signaling an age where rad onc is actively being minimized. People have always tried to come up with ways to eliminate or reduce RT, and its not even new for breast (the oncotype dx DCIS data has been around for over a decade at this point) and people have been doing RT breast omission studies since breast RT became a standard of care.

To me, trying to keep breast and prostate as our bread and butter and clinging on to how things have always been done is a surefire way to become "logs floating in the stream of life." Rad onc is changing, oversupply is real, and there is not likely going to be a "soft landing" for people not willing/able to adapt with the changing landscape of oncology. Conversely, I actually think an overall larger pool of rad oncs is actually going to help the field in the long, long term (not salary wise though unfortunately). The smaller the specialty we are, the easier it would be for the rest of oncology to leave us behind. But the fact its, we have a bigger footprint manpower wise than we ever have had and its up to us on how to best leverage that going forward

What in the hell are you babbling about?

 

[flannery o'connor]

I offer it quite a bit. If a woman is concerned about being compliant with 5 years of an AI, i tell them a short course of RT becomes even more important to consider

I mean, couldn't we offer hypofractionatedRT only, as in no surgery as valid option? I have never had a woman choose ET or RT in the setting.